002581 Stock Overview
Shandong Sinobioway Biomedicine Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shandong Sinobioway Biomedicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.64 |
| 52 Week High | CN¥14.81 |
| 52 Week Low | CN¥7.79 |
| Beta | 0.047 |
| 1 Month Change | -13.21% |
| 3 Month Change | -1.48% |
| 1 Year Change | -26.97% |
| 3 Year Change | -45.41% |
| 5 Year Change | 56.47% |
| Change since IPO | -66.22% |
Recent News & Updates
Shandong Sinobioway Biomedicine (SZSE:002581) Is In A Good Position To Deliver On Growth Plans
Dec 05
There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump
Oct 08Recent updates
Shandong Sinobioway Biomedicine (SZSE:002581) Is In A Good Position To Deliver On Growth Plans
Dec 05There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump
Oct 08Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price
Aug 19Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues
Mar 06Shareholder Returns
| 002581 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.3% | -2.5% | -2.4% |
| 1Y | -27.0% | -7.7% | 6.6% |
Return vs Industry: 002581 underperformed the CN Pharmaceuticals industry which returned -7.7% over the past year.
Return vs Market: 002581 underperformed the CN Market which returned 6.6% over the past year.
Price Volatility
| 002581 volatility | |
|---|---|
| 002581 Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002581 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002581's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 507 | Jialin Yue | www.sinobiowaymed.com.cn |
Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates in China. The company manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate and its by-products. It also offers Anfulan, a human interferon a2b injection; Jiefu, a human interferon a2b spray; Enjingfu, a mouse nerve growth factor for injection; and Bellaph, a combined hepatitis A and B vaccine.
Shandong Sinobioway Biomedicine Co., Ltd. Fundamentals Summary
| 002581 fundamental statistics | |
|---|---|
| Market cap | CN¥7.02b |
| Earnings (TTM) | -CN¥347.55m |
| Revenue (TTM) | CN¥406.15m |
17.3x
P/S Ratio-20.2x
P/E RatioIs 002581 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002581 income statement (TTM) | |
|---|---|
| Revenue | CN¥406.15m |
| Cost of Revenue | CN¥91.72m |
| Gross Profit | CN¥314.43m |
| Other Expenses | CN¥661.98m |
| Earnings | -CN¥347.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 77.42% |
| Net Profit Margin | -85.57% |
| Debt/Equity Ratio | 0% |
How did 002581 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 20:00 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Sinobioway Biomedicine Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|